Nivolumab + Relatlimab vs Pembrolizumab with Chemotherapy for Lung Cancer (RELATIVITY1093 Trial)
Trial Summary
This drug combination is unique because it combines two immune checkpoint inhibitors, Nivolumab and Relatlimab, with Pembrolizumab and chemotherapy, potentially enhancing the immune system's ability to fight lung cancer by targeting different pathways. This approach may offer a novel strategy compared to traditional chemotherapy or single-agent immunotherapy.
12369The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Nivolumab and Pembrolizumab, both used in cancer treatments, have been associated with some side effects, including cardiotoxicity (heart-related issues) and pneumonitis (lung inflammation). These side effects are relatively rare but can be serious, occurring in a small percentage of patients.
3791011Research shows that pembrolizumab, a component of the treatment, significantly improves survival in patients with non-small cell lung cancer (NSCLC) when combined with chemotherapy. Additionally, both nivolumab and pembrolizumab are effective in treating various cancers by helping the immune system target cancer cells.
34589Eligibility Criteria
This trial is for adults with stage IV or recurrent non-squamous non-small cell lung cancer showing PD-L1 levels between 1-49%. Participants should not have had prior systemic treatment for their advanced disease.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Advanced or metastatic gastric cancer
- Gastroesophageal junction cancer
- Esophageal adenocarcinoma
- Melanoma
- Non-small cell lung cancer
- Renal cell carcinoma
- Hodgkin lymphoma
- Head and neck squamous cell carcinoma
- Urothelial carcinoma
- Colorectal cancer
- Hepatocellular carcinoma
- Esophageal squamous cell carcinoma
- Melanoma
- Non-small cell lung cancer
- Renal cell carcinoma
- Hodgkin lymphoma
- Head and neck squamous cell carcinoma
- Urothelial carcinoma
- Colorectal cancer
- Gastric cancer
- Gastroesophageal junction cancer
- Esophageal adenocarcinoma
- Melanoma
- Non-small cell lung cancer
- Renal cell carcinoma
- Hodgkin lymphoma
- Head and neck squamous cell carcinoma
- Urothelial carcinoma
- Colorectal cancer
- Gastric cancer
- Gastroesophageal junction cancer
- Esophageal adenocarcinoma
- Melanoma
- Non-small cell lung cancer
- Renal cell carcinoma
- Hodgkin lymphoma
- Head and neck squamous cell carcinoma
- Urothelial carcinoma
- Colorectal cancer
- Gastric cancer
- Gastroesophageal junction cancer
- Esophageal adenocarcinoma